David Shaw’s Prometheus Biosciences, Inc. Common Stock RXDX Stock Holding History

David Shaw’s Portfolio RXDX Stock Details RXDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-797,567	Closed	-$85.6M	–	4747
2023 Q1	$85.6M	Buy	797,567 +72,338	+10%	+$8.33M	0.09%	259
2022 Q4	$79.8M	Buy	725,229 +563,848	+349%	+$36.6M	0.09%	261
2022 Q3	$9.52M	Buy	161,381 +117,360	+267%	+$5.37M	0.01%	1390
2022 Q2	$1.24M	Sell	44,021 -24,882	-36%	-$721K	﹤0.01%	3474
2022 Q1	$2.6M	Buy	68,903 +52,432	+318%	+$2.07M	﹤0.01%	3039
2021 Q4	$651K	Buy	+16,471	New	+$516K	﹤0.01%	4245

Other funds holding RXDX

UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return

FCA

FinTrust Capital Advisors Greenville, South Carolina $591M AUM 26.89% 1-Year Est. Return

David Shaw's RXDX Position: Q2 2023 in Review

David Shaw sold out of Prometheus Biosciences, Inc. Common Stock (RXDX) in Q2 2023, closing a stake of 797,567 shares — an estimated $85.6M sold.

David Shaw first reported a position in RXDX in Q4 2021 and held it in 6 quarters. The position peaked at $85.6M in Q1 2023. 2 funds tracked by Wall St. Rank hold RXDX as of Q2 2023.

David Shaw reported no remaining Prometheus Biosciences, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
David Shaw sold 797,567 Prometheus Biosciences, Inc. Common Stock shares in Q2 2023, an estimated $85.6M.
David Shaw first reported a position in Prometheus Biosciences, Inc. Common Stock in Q4 2021 and held it in 6 quarters.
David Shaw's Prometheus Biosciences, Inc. Common Stock position peaked at $85.6M in Q1 2023.
2 funds tracked by Wall St. Rank held Prometheus Biosciences, Inc. Common Stock as of Q2 2023.

Based on D.E. Shaw & Co's 13F filing for Q2 2023, filed 14 Aug 2023.